11 February 2021 : Clinical Research
Risk Factors of Coronavirus Disease 2019-Related Mortality and Optimal Treatment Regimens: A Retrospective Study
Yuehong Wang1BC, Shuang Yao2CDEF, Xiaoling Liu3BDEF, Yinghao Cao4ABCEF, Yaling Wang5BF*, Mao Xie6AEFDOI: 10.12659/MSM.926751
Med Sci Monit 2021; 27:e926751
Table 4 The clinical treatment of the COVID-19 patients in the recovered and deceased groups.
| Totaln=97 (%) | Recoveredn=76 (%) | Deceasedn=21 (%) | P* | |
|---|---|---|---|---|
| Hormone therapy | 0.494 | |||
| No | 14 (14.43) | 10 (13.16) | 4 (19.05) | |
| Yes | 83 (85.57) | 66 (86.84) | 17 (80.95) | |
| Antiviral therapy | 0.004 | |||
| One | 25 (25.77) | 14 (18.42) | 11 (52.38) | |
| More | 72 (74.23) | 62 (81.58) | 10 (47.62) | |
| Oseltamivir | 0.789 | |||
| No | 68 (70.10) | 54 (71.05) | 14 (66.67) | |
| Yes | 29 (29.90) | 22 (75.86) | 7 (24.14) | |
| Arbidol hydrochloride | 0.181 | |||
| No | 81 (83.51) | 61 (80.26) | 20 (95.24) | |
| Yes | 16 (16.49) | 15 (19.74) | 1 (4.76) | |
| Anti-HIV drugs | 0.582 | |||
| No | 5 (5.15) | 5 (6.58) | 0 (0) | |
| Yes | 92 (94.85) | 71 (93.42) | 21 (100) | |
| Other antiviral drugs | 0.453 | |||
| No | 85 (87.63) | 65 (85.53) | 20 (95.24) | |
| Yes | 12 (12.37) | 11 (14.47) | 1 (4.76) | |
| Other supportive treatment | 0.048 | |||
| No | 41 (42.27) | 28 (36.84) | 13 (61.90) | |
| Yes | 56 (57.73) | 48 (63.16) | 8 (38.10) | |
| Anti-infection therapy | <0.001 | |||
| One | 56 (57.73) | 54 (71.05) | 2 (9.52) | |
| More | 41 (42.27) | 22 (28.95) | 19 (90.48) | |
| Gammaglobulin therapy | <0.001 | |||
| No | 48 (49.48) | 46 (60.53) | 2 (9.52) | |
| Yes | 49 (50.52) | 30 (39.47) | 19 (90.48) | |
| * values were calculated by the Student’s t-test or Wilcoxon test for continuous variables. The Chi-square test for categorical variables, and the Fisher exact test was used when the data were limited. | ||||